S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based...
Pancreatic NeoplasmNeoplasm MetastasisThe primary objective of this study is to determine whether S-1 increases overall survival when compared to 5-Fluorouracil (5-FU) in patients with metastatic pancreatic cancer previously treated with a gemcitabine-based therapy. The secondary objectives are to compare: progression free survival, overall response rate, clinical benefit and improvement in tumor related symptoms and also to assess overall safety and pharmacokinetics of S-1.
A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine...
Pancreatic CancerThe purpose is to assess the overall survival of patients receiving either UFT/LV + radiotherapy (RT) or UFT/LV + Cetuximab + RT after neo-adjuvant chemotherapy.
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
Pancreatic CancerPrimary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and erlotinib) with or without external-beam radiation therapy followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Secondary Objectives: To assess disease free survival To assess overall survival To assess patterns of local and distant failure
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Metastatic Pancreatic CancerPhase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Pancreatic CancerRATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is studying gene expression in predicting treatment response in patients receiving gemcitabine and S-1 for locally advanced unresectable or metastatic pancreatic cancer.
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Metastatic Pancreatic CancerEligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing...
Pancreatic NeoplasmsBiliary Tract Neoplasms3 moreThe purpose of this trial is to determine whether a mucosa-to-mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate.
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic...
Pancreatic CancerRATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bevacizumab with docetaxel may kill more tumor cells. PURPOSE: This randomized phase II trial is studying bevacizumab and docetaxel to see how well they work compared to bevacizumab alone in treating patients with metastatic pancreatic cancer.
A Study of MLN8054 in Patients With Advanced Solid Tumors
Breast NeoplasmColon Neoplasm2 moreThe purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase.
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan...
Resected Pancreatic CancerPancreatic Cancer1 moreTo verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. Primary Endpoint: Relapse-free survival (RFS) Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile